

VERSION WITH MARKINGS SHOWING CHANGES MADE

1. (Amended) A kit of parts for [gene] delivery of a gene to a recipient cell in a host[,] using a gene delivery vehicle to which a humoral response can be raised, said kit comprising a first composition of a first gene delivery vehicle comprising a nucleic acid comprising a gene to be delivered to said recipient cell and [further comprising] a second composition of a second gene delivery vehicle, said second gene delivery vehicle essentially identical to said first gene delivery vehicle, but [preferably] lacking said gene to be delivered.

2. (Amended) [A] The kit of parts according to claim 1, wherein said second composition is a vaccine and wherein said first composition is a composition for gene therapy.

3. (Amended) [A] The kit of parts according to claim 2, wherein said vaccine is [to be] administered at a time before said [gene therapy] first composition [at a moment in time] sufficient for the host to raise a neutralising humoral response to said second gene delivery vehicle.

5. (Amended twice) [A] The kit of parts according to claim 1, wherein [a] said first gene delivery vehicle and said second gene delivery vehicle are [is] of adenoviral origin.

7. (Amended) A method for delivering a gene of interest to a recipient cell in a host using a gene delivery vehicle comprising a nucleic acid comprising said gene of interest, said method comprising: administering to a host a vaccine composition comprising a first gene delivery vehicle lacking said gene of interest [to be delivered,];
allowing for a [neutralising] neutralizing humoral response to be raised by said host to said first gene delivery vehicle [lacking said gene to be delivered,]; and
administering a composition for gene therapy comprising [essentially the same] a second gene delivery vehicle having a nucleic acid comprising said gene [to be delivered] of interest in an amount greater

than [the] an amount which can be [neutralised] neutralized by said humoral response, said first gene delivery vehicle and said second gene delivery vehicle being cross-reactive.

8. (Amended) A method for [avoiding or diminishing] minimizing liver toxicity in a host of a gene delivery composition upon administration, said method comprising:
administering to a host a vaccine composition comprising a first gene delivery vehicle[, preferably] lacking
[said] a gene of interest [to be delivered,];
allowing for a [neutralising] neutralizing humoral response to be raised by said host to said first gene delivery vehicle [lacking preferably said gene to be delivered]; and
administering a composition for gene therapy comprising [essentially the same] a second gene delivery vehicle having a nucleic acid comprising said gene of interest to be delivered to said host in an amount greater than [the] an amount which can be [neutralised] neutralized by said humoral response, said first gene delivery vehicle and said second gene delivery vehicle having the same serotype.

9. (Amended twice) [A] The method according to claim 7, wherein said first gene delivery vehicle and said second gene delivery vehicle are [is] of adenoviral origin.

10. (Amended twice) A method of preparing a pharmaceutical comprising providing the kit of parts according to claim 1 together with a pharmaceutically acceptable carrier [in the preparation of a pharmaceutical for the use as a pharmaceutical].

13. (Amended twice) [A] The kit of parts according to claim 1, wherein said gene [of interest] to be delivered is interleukin-3.